@article{2ec123e465824bc998e28de39d61a330,
title = "International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders",
abstract = "Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal residual disease is important for prognosis determination and treatment planning, and it has underscored an unmet need for sensitive imaging methods that accurately assess patient response to multiple myeloma treatment. Low-dose whole-body CT has increased sensitivity compared with conventional skeletal survey in the detection of bone disease, which can reveal information leading to changes in therapy and disease management that could prevent or delay the onset of clinically significant morbidity and mortality as a result of skeletal-related events. Given the multiple options available for the detection of bone and bone marrow lesions, ranging from conventional skeletal survey to whole-body CT, PET/CT, and MRI, the International Myeloma Working Group decided to establish guidelines on optimal use of imaging methods at different disease stages. These recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.",
author = "Jens Hillengass and Saad Usmani and Rajkumar, {S. Vincent} and Durie, {Brian G.M.} and Mateos, {Mar{\'i}a Victoria} and Sagar Lonial and Cristina Joao and Anderson, {Kenneth C.} and Ram{\'o}n Garc{\'i}a-Sanz and Serra, {Elo{\'i}sa Riva} and Juan Du and {van de Donk}, Niels and Berdeja, {Jes{\'u}s G.} and Evangelos Terpos and Elena Zamagni and Kyle, {Robert A.} and {San Miguel}, Jes{\'u}s and Hartmut Goldschmidt and Sergio Giralt and Shaji Kumar and Noopur Raje and Heinz Ludwig and Enrique Ocio and Rik Schots and Hermann Einsele and Fredrik Schjesvold and Chen, {Wen Ming} and Niels Abildgaard and Lipe, {Brea C.} and Dominik Dytfeld and Wirk, {Baldeep Mona} and Matthew Drake and Michele Cavo and Lahuerta, {Juan Jos{\'e}} and Suzanne Lentzsch",
note = "Funding Information: BGMD reports personal fees from Amgen, Celgene, Janssen, and Takeda, outside of the submitted work. MVM reports personal fees from Janssen, Clegene, Takeda, Amgen, GSK, and Pharmamar, outside of the submitted work. SaL reports personal and consulting fees from Millennium Takeda, Celgene, Novartis, Amgen, Sanofi, Janssen, and BMS, outside of the submitted work. KCA reports personal fees from and is an Advisory Board member for Celgene, Millennium, Bristol Myers Squibb, Janssen, Gilead, and Sanofi Aventix, outside of the submitted work. NvdD is an Advisory Board member for and reports Grants and other support from Celgene, Janssen, BMS, Amgen, Novartis; and other support from Bayer, Servier, and Takeda, outside of the submitted work. JGB reports grants from Abbvie, Amgen, Bluebird, BMS, Celgene, Genentech, Glenmark, Janssen, Novartis, Poseida, Sanofi, Takeda, and Teva; and consultancy fees from BMS, Celgene, Karyopharm, CRISPR, Kite Pharma, and Servier paid to his institution, outside of the submitted work. ET reports Grants, Personal fees, non-finaincial support Amgen, Genesis, Janssen, and Takeda; personal fees from Celgene and BMS; and is a an Advisory Board member for Amgen, Genesis, Takeda, Janssen, and Celgene; member of SC for Amgen, Genesis, and Takeda; and is a member of IDMC for Celgene, all outside of the submited work. JSM is an Advisory Board member for Amgen, BMS, Celgene, Janssen, MSD, Novartis, Takeda, Sanofi, and Roche. HG reports other from Amgen, grants personal feels, and non-financial support from BMS, Celgene, Chugai, and Janssen; Grants and non-financial support from Sanofi; Non-financial support from Takeda; Personal fees and other support from Novartis; other support from adaptive biotechnology; and personal fees from Art Tempi, all outside the submitted work. SG reports Grants and Honoria from Celgene, Takeda, Actinuum, Johnson and Johnson, Sanofi, and Amgen; Honoria from Novartis and Jazz; is an Advisory Board member from Celgene; and is on the data safety monitoring board for BMS, all outside the submitted work. SK reports grants from Abbvie, Celgene, Janssen, Merck, Novartis, Roche, Sanofi, Takeda, and Medimmune/Astra Zeneca; and personal fees from Oncopeptides Adaptive, outside of the submitted work. NR Holds advisory roles for Amgen, Clegene, Takeda, Janssen, and BMS. HL reports grants from Amgen and Takeda; personal fees from Amgen, Takeda, Celgene, BMS, Janssen, and Pharmamar. EO reports personal fees and research support form Amgen, Mundipharma; personal fees from BMS, Oncopeptides, Bayer, Pharmamar, Abbvie, Seattle Genetics, and Tecnofarma; Research support from Array Blopharma and IDP Pharma; and personal fees and non-financial support from Celgene, Janssen, Takeda, and Novartis Oncology. HE reports grants and personal fees and is an Advisory Board member for Janssen, Celgene, and Amgen; and reports personal fees and is an Advisory board member for BMS, Takeda, and Novartis, uring the conduct of the study. JJL reports personal fees and Honoria from Janssen, Takeda, Celgene, and Amgen. SLe reports personal fees from and is the Chief Scientific Advisor for Caelum Biosciences; personal fees from and is the Study Chair for Bayer; and personal fees and is an Advisory Board member for Janssen, Takeda, BMS, Abbvie, and Proclara. JH, SU, SVR, CJ, RGS, ERS, JD, EZ, RAK, RS, FS, WMC, NA, BCL, DD, BMW, MD, MC declare no competing interests. ",
year = "2019",
month = jun,
doi = "10.1016/S1470-2045(19)30309-2",
language = "English (US)",
volume = "20",
pages = "e302--e312",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "6",
}